Goldman Sachs Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has reaffirmed a Buy rating on SpringWorks Therapeutics (NASDAQ:SWTX) and increased the price target from $47 to $52.

November 29, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Corinne Jenkins maintains a Buy rating on SpringWorks Therapeutics and raises the price target to $52.
The increase in price target by a reputable investment bank like Goldman Sachs typically signals a positive outlook on the company's future performance, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100